Supplementary Figure S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy | Synapse
September 10, 2025Open Access
Supplementary Figure S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
Key Points
Axatilimab likely improves chronic GVHD outcomes in patients previously treated with at least two systemic therapies.
Subgroup analysis reveals efficacy across adult and pediatric patients for chronic GVHD treatments.
The analysis includes a forest plot, highlighting varying responses to axatilimab based on prior therapies.
Findings support the potential of axatilimab as a viable option for chronic GVHD among those unable to achieve relief.